A "Negative"Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
A first-in-human clinical trial to treat patients with multiple sclerosis by vaccination with tolerogenic dendritic cells (tolDC), generated using Good Manufacturing Practice (GMP) will be conducted. In doing so, the feasibility and safety of administering myelin-derived peptide-pulsed tolDC in patients with MS will be assessed.
Epistemonikos ID: 4137fa2e716d1c9548b22c3adfc98824852337a4
First added on: May 12, 2024